Aebersold, Helena; Foster-Witassek, Fabienne; Aeschbacher, Stefanie; Beer, Juerg H; Blozik, Eva; Blum, Manuel; Bonati, Leo; Conte, Giulio; Coslovsky, Michael; De Perna, Maria Luisa; Di Valentino, Marcello; Felder, Stefan; Huber, Carola A; Moschovitis, Giorgio; Mueller, Andreas; Paladini, Rebecca E; Reichlin, Tobias; Rodondi, Nicolas; Stauber, Annina; Sticherling, Christian; ... (2024). Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort. Open Heart, 11(1), e002567. B M J Group 10.1136/openhrt-2023-002567
|
Text
e002567.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (1MB) | Preview |
AIMS
Direct-acting oral anticoagulants (DOACs) have, to a substantial degree, replaced vitamin K antagonists (VKA) as treatments for stroke prevention in atrial fibrillation (AF) patients. However, evidence on the real-world causal effects of switching patients from VKA to DOAC is lacking. We aimed to assess the empirical incremental cost-effectiveness of switching patients to DOAC compared with maintaining VKA treatment.
METHODS
The target trial approach was applied to the prospective observational Swiss-AF cohort, which enrolled 2415 AF patients from 2014 to 2017. Clinical data, healthcare resource utilisation and EQ-5D-based utilities representing quality of life were collected in yearly follow-ups. Health insurance claims were available for 1024 patients (42.4%). Overall survival, quality-of-life, costs from the Swiss statutory health insurance perspective and cost-effectiveness were estimated by emulating a target trial in which patients were randomly assigned to switch to DOAC or maintain VKA treatment.
RESULTS
228 patients switching from VKA to DOAC compared with 563 patients maintaining VKA treatment had no overall survival advantage over a 5-year observation period (HR 0.99, 95% CI 0.45, 1.55). The estimated gain in quality-adjusted life years (QALYs) was 0.003 over the 5-year period at an incremental costs of CHF 23 033 (€ 20 940). The estimated incremental cost-effectiveness ratio was CHF 425 852 (€ 387 138) per QALY gained.
CONCLUSIONS
Applying a causal inference method to real-world data, we could not demonstrate switching to DOACs to be cost-effective for AF patients with at least 1 year of VKA treatment. Our estimates align with results from a previous randomised trial.
Actions (login required)
 |
Edit item |